Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Sunday's Featured Story The Often-Missed Corner of Healthcare That Wall Street Is LovingSubmitted by Nathan Reiff. Posted: 3/29/2026. 
Key Points - Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: Elon's "Hidden" Company
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's common for stocks in this sector to see some of the market's wildest swings. Investors who want exposure to the healthcare space but are concerned about that turbulence might adopt a "picks and shovels" approach, focusing on companies that provide essential equipment and services rather than on higher-risk pharmaceutical names. Lab equipment stocks are often overlooked, even though some companies in this subindustry are among the largest in healthcare. Given the external factors that could affect healthcare in 2026—shifting subsidies, an aging population with greater needs, inflation, the growing role of AI, and more—core lab equipment names may look especially attractive. The companies below are major players worth a closer look for investors considering this industry. A Recent Dip Masks Thermo Fisher's Long-Term Strengths The AI bottleneck has shifted from chips to power. Goldman Sachs projects demand growing 15% per year, with 40% of AI facilities constrained by electricity shortages by 2027. One company holds $1.5 billion in backlog orders for the exact equipment these data centers need - yet Wall Street still prices it like a sleepy industrial stock. The June SpaceX IPO could change that fast. See the math Wall Street is missing before the SpaceX IPO $182 billion life sciences solutions, diagnostics, and analytical instruments company Thermo Fisher Scientific (NYSE: TMO) has had a difficult start to 2026: shares are down more than 15% year-to-date (YTD), and the company recently moved into TradeSmith's red zone for financial health. A significant portion of that weakness reflects tariffs and foreign-exchange volatility, which together pressured margins by more than 100 basis points in 2025. There are still bright spots in Thermo Fisher's performance. In Q4 2025, revenue of $12.2 billion rose 7% year-over-year (YOY), beating analyst estimates by roughly $250 million. Adjusted earnings per share (EPS) also topped forecasts at $6.57. Recent product launches, such as the Orbitrap Astral Zoom mass spectrometer and new bioreactor offerings, likely contributed to that momentum. Thermo Fisher's broad product portfolio should provide a cushion against external pressures. Even if guidance for 2026 is modest—revenue is expected to rise 4% to 6%—improving EBITDA margins and solid underlying customer demand are positive signs. Analysts remain bullish: 17 of 19 rate the company a Buy or equivalent, and consensus estimates imply more than 29% upside potential. Danaher's Business May Be Improving, Even as Guidance Remains Modest Danaher Corp. (NYSE: DHR) shares are down nearly 20% YTD; the instruments, consumables, and reagents firm faces similar headwinds to those affecting Thermo Fisher. While 2026 guidance points to modest core revenue growth of 3% to 6% YOY, the latest quarter included top- and bottom-line beats and $5.3 billion in free cash flow for 2025. Two potential growth drivers for 2026 are Danaher's bioprocessing business, expected to deliver high-single-digit revenue growth driven by strong monoclonal antibody demand, and diagnostics. Diagnostics should benefit from FDA clearances, and equipment orders appear to be improving after a prolonged slump—trends that could support sales growth. Analysts are reasonably optimistic about DHR, forecasting roughly 12.3% earnings growth over the next year and about 35% upside in share price. That outlook is reflected in ratings: 19 of 22 analysts currently rate the stock a Buy. Agilent's Biocare Purchase Could Be a Catalyst Agilent Technologies (NYSE: A) looks a bit behind some peers based on its latest earnings, which showed tepid 4.4% YOY revenue growth and slight misses on both revenue and earnings versus expectations. However, Agilent may have a growth catalyst in its recent acquisition of Biocare Medical, which should strengthen its position in cancer diagnostics. Although the Biocare purchase cost nearly $1 billion, it should add recurring revenue in a growing and higher-margin area compared with some of Agilent's existing businesses. That could help lift operating margins (Agilent's stood at 24.6% in the most recent quarter). Despite about a 17% YTD decline, analysts see roughly 42% upside for Agilent shares. Wall Street rates the stock a Moderate Buy overall, with 13 of 16 ratings at Buy or similar. | 
0 Response to "We're excited to have you on board"
Post a Comment